title: Targeting innate immunity for treatment of type 1 diabetes.
authors.affiliation: Division of Immunology, Allergy & Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
authors.forename: Kyle J
authors.initials: KJ
authors.lastname: Bednar
authors.forename: William M
authors.initials: WM
authors.lastname: Ridgway
mesh_terms: D056704:Adaptive Immunity / Q000187:drug effects; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000276:immunology / Q000628:therapy*; D004195:Disease Models, Animal; D006801:Humans; D061148:Hygiene Hypothesis; D007113:Immunity, Innate / Q000187:drug effects; D018836:Inflammation Mediators / Q000378:metabolism; D050417:Insulin-Secreting Cells / Q000187:drug effects* / Q000276:immunology; D016688:Mice, Inbred NOD; D018345:Mice, Knockout; D058990:Molecular Targeted Therapy; D053594:Myeloid Differentiation Factor 88 / Q000378:metabolism; D051197:Toll-Like Receptor 4 / Q000235:genetics / Q000276:immunology / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D018836:Inflammation Mediators; D053594:Myeloid Differentiation Factor 88; C495345:TLR4 protein, human; D051197:Toll-Like Receptor 4
keywords: TLR4; Type 1 diabetes; immune tolerization; innate immune therapy; reversal of Type 1 diabetes